Cancer Research The Future of Cancer Research: Science and Patient Impact  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goerge, T.
Right arrow Articles by Schneider, S. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goerge, T.
Right arrow Articles by Schneider, S. W.
[Cancer Research 66, 7766-7774, August 1, 2006]
© 2006 American Association for Cancer Research


Endocrinology

Tumor-Derived Matrix Metalloproteinase-1 Targets Endothelial Proteinase-Activated Receptor 1 Promoting Endothelial Cell Activation

Tobias Goerge1,6, Alexej Barg2, Eva-Maria Schnaeker1, Birgit Poppelmann1, Victoria Shpacovitch1, Anke Rattenholl1, Christian Maaser5, Thomas A. Luger1,4, Martin Steinhoff1,3 and Stefan W. Schneider1

1 Department of Dermatology, 2 Institute of Physiology II, 3 Interdisziplinäres Zentrum für Klinische Forschung Münster; 4 Ludwig Boltzmann Institute for Immunobiology and Cell Biology of the Skin; and 5 Department of Medicine B, University of Münster, Münster, Germany; and 6 Center for Blood Research Institute for Biomedical Research, Department of Pathology, Harvard Medical School, Boston

Requests for reprints: Stefan W. Schneider, Department of Dermatology, University of Muenster, Von-Esmarch Strasse 58, 48149 Muenster, Germany. Phone: 49-251-83-56525; Fax: 49-251-83-56541; E-mail: sschnei{at}mednet.uni-muenster.de.

In the vascular system, circulating tumor cells interact with endothelial cells. Tumor-endothelial cross-talk transforms the intravascular milieu to a prothrombotic, proinflammatory, and cell-adhesive state called endothelial cell activation (ECA). In the present study, we analyze the potential of metastatic tumor-derived soluble factors to transform the vascular endothelium into a prothrombotic and proinflammatory activated state. Supernatant from cultured melanoma and colon cancer cells (A375, WM9, A7, and HT-29) induced an acute activation of macrovascular and microvascular endothelial cells (human umbilical vein endothelial cells and human dermal microvascular endothelial cells) as shown by intracellular calcium flux and secretion of von Willebrand factor and interleukin-8, all markers of acute ECA. This process was inhibited using specific proteinase-activated receptor 1 (PAR1) inhibitors (RWJ-58259 and SCH-79797), indicating a mediating role for endothelial thrombin receptors. Immunofluorescence, Western blot analysis, and collagenase activity assay of tumor cells and culture supernatant revealed the presence of matrix metalloproteinase-1 (MMP-1), a recently described activator of PAR1. Inhibition of MMP-1 in supernatant from cultured tumor cells significantly attenuated ECA. Additional studies using isolated human MMP-1 (5 nmol/L) proved the presence of a functional MMP-1/PAR1 axis in tumor-endothelial communication. These findings show a new pathway of tumor-endothelial cross-talk via an intravascular MMP1/PAR1 axis in microvascular and macrovascular endothelium. Inhibition of this cross-talk may be a powerful means to prevent tumor-induced ECA and thus thrombotic and inflammatory cell adhesion. (Cancer Res 2006; 66(15): 7766-74)




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
A. Agarwal, L. Covic, L. M. Sevigny, N. C. Kaneider, K. Lazarides, G. Azabdaftari, S. Sharifi, and A. Kuliopulos
Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer
Mol. Cancer Ther., September 1, 2008; 7(9): 2746 - 2757.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
B. Ho-Tin-Noe, T. Goerge, S. M. Cifuni, D. Duerschmied, and D. D. Wagner
Platelet Granule Secretion Continuously Prevents Intratumor Hemorrhage
Cancer Res., August 15, 2008; 68(16): 6851 - 6858.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. S. Blackburn, C. H. Rhodes, C. I. Coon, and C. E. Brinckerhoff
RNA Interference Inhibition of Matrix Metalloproteinase-1 Prevents Melanoma Metastasis by Reducing Tumor Collagenase Activity and Angiogenesis
Cancer Res., November 15, 2007; 67(22): 10849 - 10858.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
L. Zheng and M. Martins-Green
Molecular mechanisms of thrombin-induced interleukin-8 (IL-8/CXCL8) expression in THP-1-derived and primary human macrophages
J. Leukoc. Biol., September 1, 2007; 82(3): 619 - 629.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.